Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.
Resino
Salvador
S
Laboratorio de Epidemiología Molecular de Enfermedades Infecciosas, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. mmunoz.hgugm@salud.madrid.org
Palladino
Claudia
C
Lorente
Raquel
R
Micheloud
Dariela
D
Bellón
Jose Maria
JM
Larru
Beatriz
B
Gutiérrez
Maria Dolores Gurbindo
MD
de José
Maria Isabel
MI
Polo
Rosa
R
Muñoz-Fernández
Maria Angeles
MA
D000293:Adolescent; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D020738:Leptin / Q000097:blood*; D061466:Lopinavir; D011446:Prospective Studies; D011744:Pyrimidinones / Q000009:adverse effects* / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015415:Biomarkers; D020738:Leptin; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir